SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.

Viking Therapeutics Inc

VK2735 maintenance-study resultsshowing patients retained most of their weight loss on less-frequent injections, alongside encouraging efficacy and tolerabilitysparked a sharp rally and analyst upgrades. Traders largely praised the data and speculated about a partnership or buyout and short covering, while others cautioned about possible dilution, competition and the stocks pullback after the surge.

IonQ, Inc. develops and manufactures quantum computers. The firm specializes in quantum computing and quantum information processing. The company was founded by Christopher Monroe and Jung Sang Kim in 2015 and is headquartered in College Park, MD.

IonQ Inc

IonQs claimed real-time quantum error-correction decoder running on a standard CPU is drawing attention, with bullish traders viewing it as progress toward scalable fault-tolerant systems. Skeptics counter that the demonstration relies on simulations rather than a comparable quantum machine in hardware and question whether the news warrants the stocks move.

Infleqtion, Inc. engages in delivering neutral atom solutions for quantum computing, networking, sensing, and security. Its products are categorized into computing, sensing, and cores. The company was founded on February 7, 2007, and is headquartered in Louisville, CO.

Infleqtion Inc. - Ordinary Shares - Class A

Infleqtion Inc.

Infleqtions NVIDIA CUDA-Q Logical integration for quantum error-correction research is drawing attention, with traders viewing the reduced physical-qubit overhead as a technical milestone while others are frustrated that the news has not translated into a sustained share-price move. Speculation about further technical updates at quantum-industry events is adding to the discussion, alongside debate over the stocks volatility and broader market pressure.

Omeros Corp. operates as a biopharmaceutical company, which engages in the research, discovery, development, and commercialization of small-molecule and protein therapeutics targeting immunologic diseases. It also offers orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company was founded by Gregory A. Demopulos and Pamela Pierce Palmer on June 16, 1994 and is headquartered in Seattle, WA.

Omeros Corporation

Omeros Corp

Cantor Fitzgerald upgraded Omeros on increased confidence in Yartemleas commercial potential, driving a sharp rally as traders focused on the drugs launch and sales growth. The community largely welcomed the move, while some questioned whether the upgrade alone explained the surge and speculated about additional catalysts or institutional buying.

Xanadu Quantum Technologies Ltd. engages in the provision of quantum computing solutions for enterprise and government customers. The company was founded by Christian Weedbrook on October 2, 2025 and is headquartered in Toronto, Canada.

Xanadu Quantum Technologies Ltd. - Ordinary Shares - Class B (Sub Voting)

Xanadus lockup expiration made a large block of previously restricted shares tradable, and traders widely blame the resulting supply overhang for the sharp selloff. The community is split between buying the dip and expecting further selling, with some also concerned about dilution from the companys ATM program.

Candel Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of viral immunotherapies. Its pipeline includes CAN-2409 and CAN-3110. The company was founded by Estuardo Aguilar-Cordova in 2002 and is headquartered in Needham, MA.

Candel Therapeutics Inc

Attention centers on Candels planned BLA submission for CAN-2409 in localized prostate cancer, alongside anticipated biomarker data and manufacturing-readiness updates. Many traders are bullish on the Phase 3 results and regulatory progress, while others question whether the filing timeline is achievable and cite the CEOs planned share sale as a concern.

Voyager Technologies, Inc. engages in the defense technology and space solutions. It operates through the following segments: Defense and Space Technologies, and Starlab Space Stations. The Defense and Space Technologies segment consists of innovative mission-critical solutions to protect dynamic and contested domains. The Starlab Space Stations segment consists of a commercial space station. The company was founded by Dylan Taylor and Matthew Kuta on August 15, 2019 and is headquartered in Denver, CO.

Voyager Technologies Inc. - Ordinary Shares - Class A

VOYG is drawing attention after announcing a proposed convertible senior-notes offering, prompting concerns about potential dilution and repeated capital raises. Reactions are divided between holders viewing the pullback as a buying opportunity and traders criticizing managements financing needs.

Microsoft Corp. engages in the development and support of software, services, devices, and solutions. It operates through the following segments: Productivity and Business Processes, Intelligent Cloud, and More Personal Computing. The Productivity and Business Processes segment is composed of products and services relating to productivity, communication, and information services such as Office Commercial, Office Consumer, LinkedIn, and Dynamics business solutions. The Intelligent Cloud segment consists of public, private, and hybrid server products and cloud services for businesses and developers, as well as enterprise and partner services. The More Personal Computing segment refers to products and services including Windows operating system, Windows cloud services, Surface, HoloLens, personal computer accessories, Xbox hardware, Xbox Cloud Gaming, Microsoft News, and Microsoft Edge. The company was founded by Paul Gardner Allen and William Henry Gates, III in 1975 and is headquartered in Redmond, WA.

Microsoft Corporation

Microsoft Corp

Microsofts choppy trading and difficulty breaking through a key round-number level dominate discussion, with traders divided between optimism over analyst upgrades and Azure/Copilot momentum and concerns about weak relative performance, AI spending, and rates. The conversation also includes debate over AIs growth outlook, but no single new company development clearly explains the price action.

Aurinia Pharmaceuticals, Inc. is a clinical stage bio-pharmaceutical company, which engages in the research, development, and commercialization of therapeutic drugs. The company was founded by Robert Foster, Richard Glickman, and Michael Martin on June 16, 1993 and is headquartered in Edmonton, Canada.

Aurinia Pharmaceuticals Inc

Aurinias patent settlement with Teva, which delays generic voclosporin entry and includes Tevas acknowledgment that key patents are valid and enforceable, is driving attention. Traders view it as reducing Lupkynis competition risk and potentially strengthening Aurinias position in remaining generic lawsuits, though those cases are still ongoing and buyout speculation remains unconfirmed.

Advisorshares Trust - AdvisorShares Pure US Cannabis ETF

AdvisorShares Pure US Cannabis ETF

MSOS is drawing attention after a cannabis-sector rally tied in part to Trulieves addition to S&P indices, with traders also citing Green Thumbs share-repurchase announcement. The larger debate centers on the pending administrative judge recommendation in the federal Schedule III rescheduling process and potential 280E tax relief; bulls see a possible breakout, while skeptics question the timing and warn of another sell-the-news move.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

ADC Therapeutics to Participate in the 2026 Cantor Global Healthcare Conference

ADC Therapeutics to Participate in the 2026 Cantor Global Healthcare Conference ADC Therapeutics to Participate in the 2026 Cantor Global Healthcare Conference PR Newswire LAUSANNE, Switzerland, Sept. 3, 2026 LAUSANNE, Switzerland, Sept. 3, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT...

ADC Therapeutics (ADCT) Q2 2026 Earnings Call Transcript

@media (max-width: 768px) {
 .image-container {
 width: 100% !important;
 float: none !important;
 margin: 0 0 1rem 0 !important;
 }
 }

Image source: The Mo...

ADC Therapeutics Q2 2026 Earnings Call Transcript

On Thursday, ADC Therapeutics (NYSE:ADCT) discussed second-quarter financial results during its earnings call. The full transcript is provided below.
This content is powered by Benzinga APIs. For comprehensive financialread more...

ADC Therapeutics SA (ADCT) Reports Q2 Loss, Lags Revenue Estimates

ADC Therapeutics (ADCT) delivered earnings and revenue surprises of +42.11% and -4.48%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

ADC Therapeutics Reports Second Quarter 2026 Financial Results and Provides Operational Updates

ADC Therapeutics Reports Second Quarter 2026 Financial Results and Provides Operational Updates ADC Therapeutics Reports Second Quarter 2026 Financial Results and Provides Operational Updates PR Newswire LAUSANNE, Switzerland, Aug. 13, 2026 Second quarter 2026 net product revenue of $18.6 million...

Iovance Biotherapeutics (IOVA) Reports Q2 Loss, Tops Revenue Estimates

Iovance Biotherapeutics (IOVA) delivered earnings and revenue surprises of +35.29% and +13.73%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

ADC Therapeutics to Host Second Quarter 2026 Financial Results Conference Call on August 13, 2026

ADC Therapeutics to Host Second Quarter 2026 Financial Results Conference Call on August 13, 2026 ADC Therapeutics to Host Second Quarter 2026 Financial Results Conference Call on August 13, 2026 PR Newswire LAUSANNE, Switzerland, Aug. 6, 2026 LAUSANNE, Switzerland, Aug. 6, 2026 /PRNewswire/ -- ADC...

Alkermes (ALKS) Reports Break-Even Earnings for Q2

Alkermes (ALKS) delivered earnings and revenue surprises of +100.00% and +9.26%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

ADC Therapeutics Announces New Employee Inducement Grant

ADC Therapeutics Announces New Employee Inducement Grant ADC Therapeutics Announces New Employee Inducement Grant PR Newswire LAUSANNE, Switzerland, July 1, 2026 LAUSANNE, Switzerland, July 1, 2026 /PRNewswire/ --ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the...

ADC Therapeutics Announces Completion of Enrollment in LOTIS-7 Phase 1b ZYNLONTA Combination Trial

ADC Therapeutics Announces Completion of Enrollment in LOTIS-7 Phase 1b ZYNLONTA Combination Trial ADC Therapeutics Announces Completion of Enrollment in LOTIS-7 Phase 1b ZYNLONTA Combination Trial PR Newswire LAUSANNE, Switzerland, June 30, 2026 100 r/r DLBCL patients treated at the selected 150...

ADC Therapeutics SA is a clinical-stage biotechnology company, which engages in the research and development and commercialization of targeted antibody drug conjugates for patients with hematological malignancies and solid tumors. Its clinical-stage product candidates include loncastuximab tesirine, camidanlumab tesirine, and ADCT-602. The company was founded by Christopher Martin on June 6, 2011 and is headquartered in Epalinges, Switzerland.

Adc Therapeutics SA

ADC Therapeutics To Cut About 17% Of Its Staff – A Look At Some Key Details

Equity

Bullish Sentiment

Job displacement

Market bubble / overvaluation

Loss of human oversight / control

Killer robots 🤖

As AI spending accelerates across hyperscalers and valuations climb to historic highs, investors and workers alike are increasingly debating the risks the technology poses - from job displacement to fears about losing human oversight over increasingly autonomous systems. What do you think is the biggest threat AI poses? Vote and explain your reasoning in the comments.

Feed

News

Sentiment

Earnings

Fundamentals

Info

ADCT Adc Therapeutics SA

Fundamentals

Latest ADCT News